A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

Astellas Pharma Inc398 enrolled

Overview

A study to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men.

A 2 arm study ( 1 Active, 1 Placebo) to evaluate solifenacin succinate in combination with tamsulosin for the treatment of residual OAB symptoms in men

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

398

Conditions

Urinary Incontinence

Interventions

solifenacin succinateDRUG

Oral

tamsulosinDRUG

oral

placeboDRUG

oral

Eligibility

Sex: MALEMin age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Symptoms of Overactive Bladder (OAB) Exclusion Criteria: * Current use of antimuscarinic therapy * Evidence of a urinary tract infection

Locations (74)

Outcomes

Primary Outcomes

Change in micturitions per 24 hours from baseline to end of treatment

Time frame: 18 weeks

Secondary Outcomes

Change in urgency episodes per 24 hours from baseline to end of treatment

Time frame: 18 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Unnamed facility

Birmingham, Alabama, United States

Unnamed facility

Phoenix, Arizona, United States

Unnamed facility

Tuscon, Arizona, United States

Unnamed facility

Atherton, California, United States

Unnamed facility

Beverly Hills, California, United States

Unnamed facility

Buena, California, United States

Unnamed facility

Buena Park, California, United States

Unnamed facility

Carmichael, California, United States

Unnamed facility

Culver City, California, United States

Unnamed facility

Fresno, California, United States

...and 64 more locations